linsitinib + erlotinib + paclitaxel + Bortezomib + Dexamethasone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Apr 16, 2014 → Dec 21, 2016
NCT ID
NCT02057380About linsitinib + erlotinib + paclitaxel + Bortezomib + Dexamethasone
linsitinib + erlotinib + paclitaxel + Bortezomib + Dexamethasone is a phase 2 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02057380. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02057380 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors